Start with
NEXAVAR® (sorafenib) as a foundation for a systemic treatment plan1-5

10.7 months median OS achieved with NEXAVAR (95% CI, 9.4-13.3) vs 7.9 months with placebo (95% CI, 6.8-9.1) in the SHARP trial: an international, multicenter, randomized, double blind, placebo-controlled trial in patients with uHCC (N=602)1

Efficacy and Safety in uHCC

Efficacy and Safety in uHCC

Dosing in uHCC

Dosing in uHCC

Indications for NEXAVAR

NEXAVAR is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Efficacy and Safety in uHCC

Efficacy and Safety in uHCC

Dosing in uHCC

Dosing in uHCC